Search

Publications

Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D.

Read more

Application forms

The deadline for the EHA Corporate Sponsor application is September 6, 2024, at 13:00 (CEST). Interested in becoming an EHA sponsor? Below you will find all the application forms for all the available EHA Sponsor Programs.

Read more

EHA-SWG Scientific Meeting on Red Cell and Iron Metabolism Defects: From Basic Science to Clinical Case Application

Dates: October 12-14, 2023
Location: Budapest, Hungary
Chairs: A Taher & A Iolascon
Collaborating SWG: EHA Specialized Working Group on Red Cells and Iron

 Registration is closed

RegistrationRegistration is closed. Visit this page for more information.

Read more

Pivotal Ruxolitinib Data Shows Promise for Patients with PV.

 

Polycythemia vera (PV) is a chronic, incurable blood cancer with limited treatment options. If uncontrolled, PV can cause serious cardiovascular complications, such as stroke and heart attack.

Read more

EHA25 Virtual | News Room

Welcome to the news room of EHA25 Virtual where you can find the most relevant news items.

Read more

Meeting Program

All times are in GMT-3, local time in Brazil.

Read more

EHA Pediatric Course 2019

Dates: April 3-6, 2019
Location: Hotel Riviera, Sorrento, Italy

Pediatric Hemato-Oncology is a very specialized branch of hematology.

Read more

Press Release: Economic burden of blood disorders in EU is €23 billion

The economic burden of blood disorders across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.

Read more